Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Bio-Techne Corporation's quarterly P/E stands at 40.8x, down 61.0% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 42.6% YoY to 20.8x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 125.96 | 40.83 | 61.26 | 57.95 | — | 104.70 | 81.85 | 95.15 | 71.65 | 56.77 | 113.47 | 54.90 | 43.42 |
| — | -61.0% | -25.2% | -39.1% | — | +84.4% | -27.9% | +73.3% | +65.0% | +31.6% | +69.8% | +70.1% | -23.8% | |
| P/S Ratio | 7.44 | 6.58 | 7.80 | 7.59 | 6.32 | 7.37 | 9.74 | 11.12 | 9.40 | 9.31 | 11.33 | 9.95 | 10.97 |
| — | -10.6% | -19.9% | -31.8% | -32.8% | -20.8% | -14.0% | +11.8% | -14.3% | -8.7% | -8.2% | -6.8% | -10.8% | |
| P/B Ratio | 4.82 | 3.93 | 4.59 | 4.42 | 4.18 | 4.62 | 5.57 | 6.02 | 5.56 | 5.61 | 6.29 | 5.52 | 6.72 |
| — | -14.8% | -17.5% | -26.5% | -24.9% | -17.7% | -11.5% | +9.1% | -17.2% | -11.6% | -14.3% | -16.1% | -19.4% | |
| P/FCF | 35.36 | 26.43 | 30.18 | 97.86 | 21.47 | 75.16 | 37.31 | 58.84 | 50.03 | 43.76 | 45.24 | 60.18 | 45.54 |
| — | -64.8% | -19.1% | +66.3% | -57.1% | +71.8% | -17.5% | -2.2% | +9.9% | -43.4% | -21.3% | -2.7% | +14.5% | |
| EV / EBITDA | 44.09 | 20.78 | 29.72 | 31.07 | 637.92 | 36.22 | 39.55 | 48.03 | 39.86 | 30.89 | 48.54 | 33.84 | 27.77 |
| — | -42.6% | -24.9% | -35.3% | +1500.6% | +17.3% | -18.5% | +42.0% | +43.5% | +7.3% | +35.7% | -4.0% | -17.5% | |
| EV / EBIT | 91.47 | 27.43 | 44.43 | 43.93 | — | 59.59 | 65.45 | 77.27 | 66.67 | 44.75 | 84.68 | 52.45 | 36.66 |
| — | -54.0% | -32.1% | -43.2% | — | +33.2% | -22.7% | +47.3% | +81.9% | +18.4% | +91.0% | +92.9% | -16.6% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Bio-Techne Corporation's operating margin was 24.2% in Q3 2026, up 5.8 pp QoQ and up 12.0 pp YoY. This marks the 4th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 12.9% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.8% | 66.9% | 64.6% | 65.6% | 62.7% | 67.9% | 65.3% | 63.2% | 66.4% | 67.4% | 64.8% | 66.9% | 67.9% |
| — | -1.4% | -1.0% | +3.8% | -5.6% | +0.6% | +0.8% | -5.4% | -2.2% | -1.9% | -4.1% | +0.4% | -2.3% | |
| Operating Margin | 8.4% | 24.2% | 18.4% | 16.6% | -7.5% | 12.2% | 16.0% | 13.8% | 15.0% | 22.1% | 13.9% | 20.2% | 31.4% |
| — | +98.0% | +15.3% | +20.4% | -150.3% | -44.6% | +14.5% | -31.5% | -52.3% | -19.0% | -44.2% | -3.4% | +12.2% | |
| Net Margin | 6.0% | 16.4% | 12.8% | 13.3% | -5.6% | 7.1% | 11.7% | 11.6% | 13.3% | 16.2% | 10.1% | 18.4% | 25.1% |
| — | +129.5% | +9.4% | +14.8% | -142.1% | -55.8% | +16.6% | -37.0% | -47.1% | -32.3% | -45.3% | -44.6% | +17.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 3.7% | 2.5% | 1.9% | 2.0% | -0.9% | 1.1% | 1.7% | 1.6% | 2.0% | 2.5% | 1.4% | 2.6% | 3.9% |
| — | +126.0% | +15.5% | +23.1% | -145.2% | -55.3% | +19.3% | -37.9% | -49.2% | -34.7% | -50.4% | -50.4% | +8.6% | |
| ROA | 2.8% | 2.0% | 1.5% | 1.5% | -0.7% | 0.9% | 1.3% | 1.2% | 1.5% | 1.8% | 1.0% | 1.9% | 2.9% |
| — | +136.8% | +16.7% | +21.6% | -145.4% | -52.8% | +28.9% | -34.7% | -48.1% | -36.4% | -52.8% | -51.0% | +7.6% | |
| ROIC | 3.4% | 2.6% | 1.9% | 1.6% | -0.8% | 1.3% | 1.5% | 1.3% | 1.5% | 2.1% | 1.2% | 1.8% | 3.2% |
| — | +105.9% | +21.2% | +26.5% | -154.4% | -40.2% | +28.6% | -29.1% | -53.9% | -26.5% | -54.6% | -19.1% | -2.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Bio-Techne Corporation's Debt/EBITDA ratio is 2.9x, down from 4.4x last quarter — at a moderate level that warrants monitoring. The current ratio has improved 21.1% YoY to 4.49x, strengthening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.14 | 0.17 | 0.20 | 0.23 | 0.21 | 0.19 | 0.19 | 0.20 | 0.25 | 0.28 | 0.28 | 0.23 |
| — | -33.7% | -8.2% | +7.6% | +14.1% | -14.6% | -32.8% | -32.2% | -12.3% | -2.1% | +78.8% | +41.0% | +20.7% | |
| Debt / EBITDA | 2.09 | 2.91 | 4.43 | 5.48 | 136.59 | 6.39 | 5.30 | 5.86 | 5.68 | 5.25 | 8.44 | 6.51 | 3.75 |
| — | -54.4% | -16.4% | -6.4% | +2305.4% | +21.8% | -37.2% | -10.1% | +51.6% | +18.6% | +176.2% | +58.1% | +22.3% | |
| Current Ratio | 3.46 | 4.49 | 4.54 | 4.22 | 3.46 | 3.71 | 3.94 | 4.56 | 3.87 | 4.08 | 4.37 | 4.63 | 4.84 |
| — | +21.1% | +15.3% | -7.6% | -10.7% | -9.1% | -9.9% | -1.4% | -19.9% | +0.8% | -0.8% | +15.4% | +40.6% | |
| Quick Ratio | 2.38 | 3.18 | 3.08 | 2.81 | 2.38 | 2.58 | 2.77 | 3.26 | 2.75 | 2.88 | 3.03 | 3.17 | 3.50 |
| — | +23.2% | +11.2% | -13.8% | -13.3% | -10.4% | -8.7% | +2.8% | -21.5% | +1.2% | -3.9% | +8.6% | +32.7% | |
| Interest Coverage | 12.57 | 23.43 | 24.39 | 17.36 | -9.50 | 20.07 | 20.96 | 19.46 | 17.60 | 16.25 | 8.71 | 11.13 | 24.86 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TECH stock.
Bio-Techne Corporation's current P/E is 126.0x. The average P/E over the last 3 quarters is 53.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bio-Techne Corporation's current operating margin is 8.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bio-Techne Corporation's business trajectory between earnings reports.